Task 2 AAV-K55-GRD-C24 efficacy (double dose, single time point) Body Weight.pptx

syn70747581

Created By Karis Weisgerber karisweisgerber

Id: 8a96b801-4234-48ca-897c-2ad61f2590df
assay: weight
organ: nerves
species: Mus musculus
studyId: syn31821155
dataType: physiology parameter
entityId: syn70747581
platform: Not Applicable
Component: ImagingAssayTemplate
diagnosis: Neurofibromatosis type 1
studyName: NTAP NF1 Gene Replacement Initiative- Development of a gene replacement therapy for cutaneous neurofibromas related to NF1
tumorType: Not Applicable
fileFormat: powerpoint
initiative: Gene Replacement Initiative
dataSubtype: processed
nf1Genotype: -/-
nf2Genotype: -/-
compoundDose: 1
compoundName: AAV9-GRD-C24
individualID: A766 A767 A768 A769 A770 A761 A762 A763 A764 A765
resourceType: result
fundingAgency: NTAP
timepointUnit: weeks
compoundDoseUnit: 1000000000000
experimentalCondition: One dosage 1e12 AAV9-GRD-C24 or 1e12 K55-GRD-C24 through tail vein, 5 mg/kg desamethasone every other day from Day 1.

Task 2 AAV-K55-GRD-C24 efficacy (double dose, single time point) Body Weight.pptx page is loading…